Lymphoma Antibody
Lymphoma Antibody
T-Cell Leukemia / Lymphoma 1A Antibody |
|||
abx116012-100g | Abbexa | 100 µg | Ask for price |
T-Cell Leukemia / Lymphoma 1A Antibody |
|||
abx116012-10g | Abbexa | 10 µg | 612.5 EUR |
T-Cell Leukemia / Lymphoma 1A Antibody |
|||
abx116012-200g | Abbexa | 200 µg | Ask for price |
Anapastic Lymphoma Kinase (ALK) Antibody |
|||
20-abx119392 | Abbexa |
|
|
Anapastic Lymphoma Kinase (ALK) Antibody |
|||
abx122001-100ug | Abbexa | 100 ug | 469.2 EUR |
Anapastic Lymphoma Kinase (ALK) Antibody |
|||
abx122523-100ug | Abbexa | 100 ug | 469.2 EUR |
Anapastic Lymphoma Kinase (ALK) Antibody |
|||
abx122756-100ug | Abbexa | 100 ug | 469.2 EUR |
Anapastic Lymphoma Kinase (ALK) Antibody |
|||
abx033503-400ul | Abbexa | 400 ul | 627.6 EUR |
Anapastic Lymphoma Kinase (ALK) Antibody |
|||
abx033503-80l | Abbexa | 80 µl | 343.2 EUR |
Anapastic Lymphoma Kinase (ALK) Antibody |
|||
abx010333-100ug | Abbexa | 100 ug | 526.8 EUR |
Anapastic Lymphoma Kinase (ALK) Antibody |
|||
20-abx012794 | Abbexa |
|
|
Anapastic Lymphoma Kinase (ALK) Antibody |
|||
20-abx012911 | Abbexa |
|
|
Anapastic Lymphoma Kinase (ALK) Antibody |
|||
abx224320-100ug | Abbexa | 100 ug | 493.2 EUR |
Anapastic Lymphoma Kinase (ALK) Antibody |
|||
abx224449-100ug | Abbexa | 100 ug | 493.2 EUR |
Anapastic Lymphoma Kinase (ALK) Antibody |
|||
abx412203-50ug | Abbexa | 50 ug | 610.8 EUR |
Anapastic Lymphoma Kinase (Alk) Antibody |
|||
abx431093-200ul | Abbexa | 200 ul | 460.8 EUR |
Anaplastic Lymphoma Kinase (ALK) Antibody |
|||
20-abx128738 | Abbexa |
|
|
Anaplastic lymphoma kinase Antibody (Alk) |
|||
F53252-0.08ML | NSJ Bioreagents | 0.08 ml | 140.25 EUR |
Description: Anaplastic lymphoma kinase is a neuronal orphan receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK. [UniProt] |
|||
Anaplastic Lymphoma Kinase Antibody (ALK) |
|||
F50550-0.08ML | NSJ Bioreagents | 0.08 ml | 140.25 EUR |
Description: Anaplastic lymphoma kinase, a member of the insulin receptor subfamily of Tyr protein kinases, is an orphan receptor. It appears to play an important role in the normal development and function of the nervous system. This Type I membrane protein is expressed in brain and CNS and in the small intestine and testis, but not in normal lymphoid cells. A form of non-Hodgkin's lymphoma is characterized by a chromosomal translocation t(2;5)(p23;q35) that involves NPM1 and ALK. The protein contains 1 LDL-receptor class A domain and 2 putative MAM domains. |
|||
ALK Antibody / Anaplastic lymphoma kinase |
|||
R20381-0.1ML | NSJ Bioreagents | 100ul | 409 EUR |
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V8780-100UG | NSJ Bioreagents | 100ug | 424.15 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene,NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V8780-20UG | NSJ Bioreagents | 20ug | 186.15 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene,NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V8780SAF-100UG | NSJ Bioreagents | 100ug | 424.15 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene,NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V8812-100UG | NSJ Bioreagents | 100ug | 424.15 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene,NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V8812-20UG | NSJ Bioreagents | 20ug | 186.15 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene,NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V8812SAF-100UG | NSJ Bioreagents | 100ug | 424.15 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene,NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V8859-100UG | NSJ Bioreagents | 100ug | 349.3 EUR |
Description: Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase of the insulin receptor superfamily. ALK is typically expressed at low levels in regions of the developing central and peripheral nervous system. |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V8859-20UG | NSJ Bioreagents | 20ug | 153.3 EUR |
Description: Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase of the insulin receptor superfamily. ALK is typically expressed at low levels in regions of the developing central and peripheral nervous system. |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V8859SAF-100UG | NSJ Bioreagents | 100ug | 349.3 EUR |
Description: Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase of the insulin receptor superfamily. ALK is typically expressed at low levels in regions of the developing central and peripheral nervous system. |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V8896-100UG | NSJ Bioreagents | 100ug | 349.3 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene,NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V8896-20UG | NSJ Bioreagents | 20ug | 153.3 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene,NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V8896SAF-100UG | NSJ Bioreagents | 100ug | 349.3 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene,NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V3817-100UG | NSJ Bioreagents | 100 ug | 424.15 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene, NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V3817-20UG | NSJ Bioreagents | 20 ug | 186.15 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene, NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V3817SAF-100UG | NSJ Bioreagents | 100 ug | 424.15 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene, NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V3818-100UG | NSJ Bioreagents | 100 ug | 424.15 EUR |
Description: Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK. [UniProt] |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V3818-20UG | NSJ Bioreagents | 20 ug | 186.15 EUR |
Description: Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK. [UniProt] |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V3818SAF-100UG | NSJ Bioreagents | 100 ug | 424.15 EUR |
Description: Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK. [UniProt] |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V3998-100UG | NSJ Bioreagents | 100 ug | 349.3 EUR |
Description: Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK. [UniProt] |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V3998-20UG | NSJ Bioreagents | 20 ug | 153.3 EUR |
Description: Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK. [UniProt] |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V3998IHC-7ML | NSJ Bioreagents | 7 ml | 349.3 EUR |
Description: Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK. [UniProt] |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V3998SAF-100UG | NSJ Bioreagents | 100 ug | 349.3 EUR |
Description: Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK. [UniProt] |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V9339-100UG | NSJ Bioreagents | 100ug | 349.3 EUR |
Description: Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. [UniProt] |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V9339-20UG | NSJ Bioreagents | 20ug | 153.3 EUR |
Description: Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. [UniProt] |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V9339SAF-100UG | NSJ Bioreagents | 100ug | 349.3 EUR |
Description: Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. [UniProt] |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V7410-100UG | NSJ Bioreagents | 100 ug | 349.3 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene, NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V7410-20UG | NSJ Bioreagents | 20 ug | 153.3 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene, NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V7410IHC-7ML | NSJ Bioreagents | 7 ml | 349.3 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene, NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
ALK Antibody / Anaplastic Lymphoma Kinase |
|||
V7410SAF-100UG | NSJ Bioreagents | 100 ug | 349.3 EUR |
Description: The wild-type anaplastic lymphoma kinase (ALK) protein is a 200kDa transmembrane receptor tyrosine kinase. Its expression is restricted to a few scattered cells in the nervous system (some glial cells and neurons, and a few endothelial cells and pericytes. The hybrid gene, NPM-ALK, created by the t(2;5)(p23;q35) chromosomal translocation encodes part of the nucleolar phosphoprotein, nucleophosmin (NPM), joined to the entire cytoplasmic portion of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. As a consequence, the ALK gene comes under the control of the NPM promoter, which induces a permanent and ubiquitous transcription of the NPM-ALK hybrid gene, resulting in the production of a 80kDa NPM-ALK chimeric protein. This translocation is found in anaplastic large cell lymphomas (ALCL). Reportedly, expression of ALK indicates a better prognosis. Approximately 5%-10% of non-small cell lung carcinomas also express ALK protein producing a cytoplasmic staining pattern. This MAb also reacts with blood vessels that serves as an internal positive control. |
|||
B-Cell CLL/Lymphoma 9 (Bcl9) Antibody |
|||
20-abx104977 | Abbexa |
|
|
B-Cell CLL/Lymphoma 3 (Bcl3) Antibody |
|||
20-abx102095 | Abbexa |
|
|
B-Cell CLL/Lymphoma 3 (Bcl3) Antibody |
|||
20-abx102096 | Abbexa |
|
|
B-Cell CLL/Lymphoma 9 (Bcl9) Antibody |
|||
20-abx129701 | Abbexa |
|
|
B-Cell CLL/Lymphoma 6 (BCL6) Antibody |
|||
20-abx121029 | Abbexa |
|
|
B-Cell CLL/Lymphoma 6 (BCL6) Antibody |
|||
20-abx121304 | Abbexa |
|
|
B-Cell CLL/Lymphoma 3 (BCL3) Antibody |
|||
20-abx125560 | Abbexa |
|
|
B-Cell CLL/Lymphoma 6 (BCL6) Antibody |
|||
20-abx133381 | Abbexa |
|
|
B-Cell CLL/Lymphoma 9 (BCL9) Antibody |
|||
20-abx005211 | Abbexa |
|
|
B-Cell CLL/Lymphoma 6 (BCL6) Antibody |
|||
20-abx005414 | Abbexa |
|
|
B-Cell CLL/Lymphoma 6 (Bcl6) Antibody |
|||
abx037682-100ug | Abbexa | 100 ug | 469.2 EUR |
B-Cell CLL/Lymphoma 6 (BCL6) Antibody |
|||
abx025320-100ul | Abbexa | 100 ul | 627.6 EUR |
B-Cell CLL/Lymphoma 3 (BCL3) Antibody |
|||
20-abx211821 | Abbexa |
|
|
B-Cell CLL/Lymphoma 6 (BCL6) Antibody |
|||
20-abx211822 | Abbexa |
|
|
B-Cell CLL/Lymphoma 3 (BCL3) Antibody |
|||
20-abx212732 | Abbexa |
|
|
B-Cell CLL/Lymphoma 6 (BCL6) Antibody |
|||
20-abx212733 | Abbexa |
|
|
B-Cell CLL/Lymphoma 3 (BCL3) Antibody |
|||
abx230848-100ug | Abbexa | 100 ug | 577.2 EUR |
B-Cell CLL/Lymphoma 6 (BCL6) Antibody |
|||
abx230849-100ug | Abbexa | 100 ug | 577.2 EUR |
B-Cell CLL/Lymphoma 9 (Bcl9) Antibody |
|||
20-abx175543 | Abbexa |
|
|
B-Cell CLL/Lymphoma 6 (BCL6) Antibody |
|||
20-abx325149 | Abbexa |
|
|
B-Cell CLL/Lymphoma 6 (BCL6) Antibody |
|||
20-abx327517 | Abbexa |
|
|
B-Cell CLL/Lymphoma 6 (BCL6) Antibody |
|||
20-abx328707 | Abbexa |
|
|
B-Cell CLL/Lymphoma 6 (BCL6) Antibody |
|||
abx331642-100ul | Abbexa | 100 ul | 510 EUR |